Gene editing, once a theoretical ambition, has matured into a revolutionary frontier in biotechnology. Technologies like CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) have unlocked ...

By Brad Plumer and Lisa Friedman Reporting from Washington The Trump administration is considering several executive orders aimed at speeding up the construction of nuclear power plants to help ...

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy contract development and manufacturing organization (CDMO), has manufactured viral vector with its AAV Curator Platform ...

CRISPR Ther­a­peu­tics has re­vealed promis­ing but ear­ly da­ta from its first clin­i­cal study of a gene edit­ing ther­a­py to low­er the risk of heart dis­ease … ...

Prasad's social media reveals criticism of Verve's 1st-gen PCSK9 approach, which may signal negative sentiment for CRISPR to navigate. Unlock your all-in-one trading dashboard with real-time ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share.

Cell and gene therapy start-up NKure Therapeutics and international gene-editing company CRISPR Therapeutics have entered into a partnership to co-develop and co-commercialise CTX112 — a next ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy Casgevy. While Vertex handles the market, CRISPR has been focused on its ...

The well-established platform allows for the ability to support the exacting viral vector manufacturing needs of the NCH NK cells created on the hospital's patented universal-donor NK cell platform.

CRISPR Therapeutics stock is heavily shorted in the weeks going into earnings The short-sellers are betting against the name in a big way, with more than 20 million shares sold short as of the ...

Now, a first-in-human clinical trial is testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal cancers. The results show encouraging signs of safety ...